Evidence map›Paper›PMID 42180871›Full record

ArticleTranslational cancer research2026

Integrated single-cell and bulk RNA sequencing reveals novel biomarkers of invasive adenocarcinoma subtypes in lung adenocarcinoma.

Xiaoming Wu, Xuxia Ye, Bo Wang, Zhoule Li, Chengnan Fang, Jian Xu, Mengli Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiaoming Wu *Department of Radiology, Jinhua People's Hospital, Affiliated Jinhua Hospital of Wenzhou Medical University, Jinhua, China.
Xuxia Ye *School of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou, China.
Bo WangDepartment of Radiology, Jinhua People's Hospital, Affiliated Jinhua Hospital of Wenzhou Medical University, Jinhua, China.
Zhoule LiDepartment of Radiology, Jinhua People's Hospital, Affiliated Jinhua Hospital of Wenzhou Medical University, Jinhua, China.
Chengnan FangSchool of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou, China.
Jian XuSchool of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou, China.
Mengli WuSchool of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Lung adenocarcinoma (LUAD) is one of the most common lung cancer subtypes worldwide, and its aggressive subtype invasive adenocarcinoma (IAC) has low survival rates. The precise identification of IAC is vital for the clinical diagnosis and treatment. The purpose of this study is to identify novel biomarkers for LUAD using single-cell and bulk RNA sequencing, so as to provide theoretical basis and practical support for the diagnosis, treatment and prognosis evaluation of lung invasive adenocarcinoma. Methods: We employed a combination of transcriptomic analysis and single-cell analysis to investigate the molecular characteristics and immune microenvironment of four subtypes of LUAD, including atypical adenomatous hyperplasia (AAH), adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA), and IAC, with the aim of screening for biomarkers to differentiate pre-invasive lesions from invasive lesions. Results: Transcriptomic and single-cell analyses revealed that IAC subtypes demonstrated the most substantial molecular differences, particularly in immune cell infiltration and immune-related gene expression. Three genes- Conclusions: This study identifies a three-gene signature (

Indexed as

invasive adenocarcinoma of the lung (IAC of the lung)Lung cancermolecular markersmulti-omics

Identifiers

PMID42180871
PMCPMC13190665

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.